ATRC - AtriCure down 9% on Kerrisdale short call

Thinly traded AtriCure ([[ATRC]] -9.4%) is under modest pressure out of the gate this morning on the heels of a bearish report from Kerrisdale Capital Management who believes its growth drivers face headwinds. Key points:The company's Convergent procedure is unlikely to gain traction considering its poor safety profile and lack of incremental benefit compared to catheter-based procedures.The total available market for its surgical ablation products is much smaller that it claims and is almost completely saturated.Other approaches, real-time mapping and pulse-field ablation, are set to revolutionize catheter ablation to the detriment of Convergent and the company's core surgical devices business.

For further details see:

AtriCure down 9% on Kerrisdale short call